T2 Biosystems Inc. is a T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories.
T2 Biosystems Inc. (TTOO) had a good day on the market for Monday February 08 as shares jumped 22.26% to close at $3.79. About 37.14 million shares traded hands on 98,459 trades for the day, compared with an average daily volume of n/a shares out of a total float of 147.96 million. After opening the trading day at $3.25, shares of T2 Biosystems Inc. stayed within a range of $3.79 to $3.20.
With today’s gains, T2 Biosystems Inc. now has a market cap of $560.75 million. Shares of T2 Biosystems Inc. have been trading within a range of $3.46 and $0.24 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
T2 Biosystems Inc provides rapid in vitro diagnostic tests to hospitals and laboratories. Its core technology is T2 Magnetic Resonance (T2MR) technology, which can detect a variety of molecular targets directly from whole blood. T2MR technology enables the T2Dx system, which is fully automated from patient sample to result for its panels focused on bacterial and fungal infections that could cause sepsis, and its pipeline panel for Lyme disease.
T2 Biosystems Inc. is based out of Lexington, MA and has some 151 employees. Its CEO is John J. Sperzel.